Background: Caffeine or ketorolac decrease the risk of retinopathy of prematurity and may act synergistically to improve beneficial effect. Combination of caffeine (Caff ) and ketorolac (Keto) to prevent oxygen-induced retinopathy was studied. Methods: Newborn rats exposed to room air (RA) or intermittent hypoxia (IH) consisting of 12% O 2 during hyperoxia (50% O 2 ) from birth (P0) had single daily IP injections of Caff from P0-P13 or saline; and/or ocular Keto (Acuvail, 0.45% ophthalmic solution) administered subcutaneously over the eyes from P5-P7. Pups were studied at P14 or placed in RA for recovery from IH (IHR) until P21. Eyes were examined for neovascularization, histopathology, growth factors, and VEGF-signaling genes. results: Severe retinal damage noted during IHR in the untreated groups evidenced by hemorrhage, neovascularization, and oxygen-induced retinopathy (OIR) pathologies were prevented with Keto/Caff treatment. Keto and/or Caff treatment in IH also promoted retinal neural development evidenced by eye opening (92%, P < 0.001 vs. 31% in the placebo-treated IH group). No corneal pathologies were noted with Keto. conclusion. Caff or Keto given individually reduced retinal neovascularization, but the two drugs given together prevented severe OIR.
r etinopathy of prematurity (ROP) is a neovascular disease in preterm neonates characterized by: (i) an the early vaso-obliterative phase (phase I) leading to ocular hypoxia and aberrant regulation of ocular vascular growth factors; and (ii) a later vaso-proliferative phase (phase II) of pathologic neovascularization leading to cicatricial formation, retinal detachment, and blindness (1, 2) . Hyperoxia and intermittent hypoxia (IH) are key risk factors for ROP. Preterm newborns experience numerous IH episodes during the first few weeks of life (3-7) with fluctuations in PaO 2 (7) . These repeated IH episodes in recurrent apnea with exposure to hyperoxia increases the risk factor for severe ROP requiring laser treatment.
Pharmacologic interventions to prevent ROP include targeting vascular endothelial growth factor (VEGF) and its coregulators of angiogenesis. Intravitreal Bevacizumab (Avastin), an irreversible VEGF blocker is used in preterm newborns with aggressive posterior ROP. The BEAT-ROP Trial (8, 9) showed superiority of Avastin compared to laser. However, use of anti-VEGF therapies during critical stages of development may result in unwanted long-term adverse effects (10, 11) .
Multifactorial pathogenesis suggests that no single pharmacologic agent that may target the complex interactions of growth factors, oxidative stress, inflammatory response, and membrane disruption currently exists to prevent ROP. We propose that synergistic pharmacologic agents may correct most of the aberrant molecular and biochemical events leading to ROP. This novel approach combines Caffeine citrate (Caff) and nonsteroidal anti-inflamatory drugs (NSAIDs) to target oxidative stress and inflammatory responses, reduce the occurrence of IH, and target some of the growth factors involved in the development of severe ROP. Caff is used worldwide for apnea prevention and to facilitate endotracheal extubation of neonates on mechanical ventilation (12) . The Caffeine for Apnea of Prematurity trial involving 2,006 preterm newborns given either placebo or Caff showed decreased severe ROP and other neonatal morbidities at 18-22 mo (13, 14) . Studies on growth factors and morphogens such as Sonic Hedgehog (15) , VEGF and hypoxia-inducible factor (HIF)-1α (16) , as well as matrix degrading enzymes (17) , indicate that Caff exerts powerful effects on these molecular events that may lead to the observed protective effect on ROP. Prostanoids are involved in the development of oxygen-induced retinopathy (OIR) and the cross-talk between VEGF, oxidative stress, and cyclooxygenase (COX) pathways (18) (19) (20) (21) (22) (23) . Ketorolac (Keto) eye drops, an ophthalmic NSAID that inhibit COX, had been used safely and had decreased ROP in ketorolac treated preterm infants compared to a historical control (23) .
Thus, we tested the hypothesis that the combined use of topical ocular Keto and systemic Caff exerts synergistic actions to prevent severe OIR in our rat model simulating apnea and IH, or brief arterial oxygen desaturations in ELGANs. We Articles administered Cafcit from the first day of life (P0) to P13 and/or ophthalmic ketorolac (Acuvail) from P5 to P7 during exposure to IH to determine whether drugs with complimentary actions given together act synergistically on retinal angiogenesis and OIR prevention.
RESULTS

Effects on Eye Opening and Somatic Growth
The ceacal period encompassing the time of conception to eye opening, is an indication of retinal neural circuitry maturation in rats. Rats open their eyes at P14. For this reason, we exposed the animals to IH from P0 to P14. This phase also coincides with phase I of ROP. Table 1 shows that at P14, eye opening occurred in 58 to 61% of pups raised in RA with placebo treatment. IH significantly decreased eye opening to 31 to 36%. Keto or Caff accelerated eye opening up to 75 and 78%, respectively and 92% when given together. ROP is most severe in undernourished ELGANs; thus, we examined the effects of IH on somatic growth. We determined percentage change from P0 in order to account for differences in body weight at birth. Although we pooled the litters to eliminate litter size differences, we found that larger dams delivered larger pups; so, there were variations in birth weight over the course of the experiments. Table 2 shows that weight accretion was lower in IH-exposed, placebo-treated animals during recovery from IH (IHR). Treatment with Keto and/or Caff in IH improved weight accretion (n = 18 pups per group).
Effect on VEGF Protein
Systemic VEGF levels (pg/ml) are presented in Table 3 . VEGF levels (n = 10 samples per group) were significantly higher in the Keto/Caff groups exposed to IH. Retinal and choroidal VEGF levels (pg/mg protein) are presented in Figures 1 and  2 (panels a and d), respectively (n = 6 samples per group). At P14 (Figure 1a) , Sal/Caff treatment in IH decreased retinal VEGF, as did treatment with Keto/Caff in IH albeit to a lesser degree. At P21, Keto/Sal and Sal/Caff decreased retinal VEGF during IHR (Figure 1d) . In the choroid, VEGF was decreased in the placebo IH group, and elevated with Keto/Sal and Keto/ Caff in IH (Figure 2a) . The response was sustained during IHR (Figure 2d) .
Effect on sVEGFR-1
Systemic sVEGFR-1 levels (pg/ml), presented in Table 3 , show decreased VEGFR-1 with Keto/Sal and Keto/Caff in RA at P14; and with all treatment groups during IH (n = 10 samples per group). Retinal and choroidal sVEGFR-1 levels (pg/mg protein) are presented in Figures 1 and 2 (panels b and e), respectively (n = 6 samples per group). At P14 (IH), retinal sVEGFR-1 levels were significantly decreased in the Sal/Sal controls and elevated in the treated groups (Figure 1b) . At P21 (IHR), the levels further declined in the Sal/Sal controls and remained elevated in the treated groups (Figure 1e ). Choroidal responses in IH and IHR were similar to those noted in the retina (Figure 2b,e) .
Effect on IGF-I
Systemic IGF-I levels (pg/mL), presented in Table 3 , show elevated IGF-I levels in response to Keto/Sal and/or Keto/ Caff in IH (n = 10 samples per group). These effects remained sustained at P21. Retinal and choroidal IGF-I levels (pg/mg protein) are presented in Figures 1 and 2 (panels c and f), respectively (n = 6 samples per group). In the retina, IGF-I levels declined in the Sal/Sal controls during IH (P14) but were elevated in all treated groups (Figure 1c) . At P21 (IHR), only those animals treated with Keto/Caff in RA and IH had higher retinal IGF-I levels (Figure 1f) . Choroidal IGF responded similarly to that of the retina during IH (Figure 2c) . At P21, choroidal IGF-I levels were elevated in all treated groups during IHR (Figure 2f ).
Effect on HIF1α
Retinal and choroidal HIF 1α (pg/mg protein) and 8-isoPGF 2α (pg/mg protein) levels are presented in Figure 3 (n = 6 samples per group). Retinal HIF 1α levels during IH are presented in Figure 3a and during IHR in Figure 3e . Choroidal HIF 1α levels during IH are presented in Figure 3c and during IHR in Figure 3g . At P14, retinal HIF 1α increased in the Sal/Sal group exposed to IH. Keto/Sal also increased retinal HIF 1α in RA while Keto/Caff treatment decreased HIF 1α in IH (Figure  3a) . During IHR, a more profound elevation in retinal HIF 1α was noted in the Sal/Sal group, suggesting IH-induced sustained HIF 1α stabilization. Treatment with Keto/Sal and Sal/Caff in IH decreased retinal HIF 1α (Figure 3e) . In the choroid, treatment with Caff and/or Keto did not appreciably change HIF 1α levels during IH (Figure 3c ), or IHR (Figure 3g) . 
Effect on 8-isoPGF2α
8-isoPGF 2α levels (biomarker for oxidative stress) in retina and choroid, are presented in Figure 3 (n = 6 samples per group). Retinal 8-isoPGF 2α levels during IH are presented in Figure 3b and during IHR in Figure 3f . Choroidal 8-isoPGF 2α levels during IH are presented in Figure 3d and during IHR in Figure 3h . At P14, retinal 8-isoPGF 2α levels increased in the Sal/Sal group exposed to IH (Figure 3b ) and remained elevated during IHR at P21 (Figure 3f) . Treatment with Keto and/ or Caff significantly reversed this response. A similar response pattern was noted in the choroid during IH (Figure 3d ) and IHR (Figure 3h) , although there was an increase with Sal/Caff treatment in RA. 
Histopathology and Immunofluorescence
Representative H & E-stained retinas and corneas from RA controls (panels a and d), Sal/Sal IHR (panels b1, b2, and e) and 
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Keto/Caff IHR (panels c and f) groups at P21 are presented in The placebo-treated IHR groups severe nerve fiber layer (NFL) vacuolization and/or loss, GCL (ganglion cell layer) nuclear atrophy, and P (photoreceptor) degeneration (panel b1, arrows, 40× magnification), as well as increased neovascularization penetrating the vitreous cavity (panel b2, arrow, 60× magnification). In addition, there was evidence of corneal degeneration (panel e, arrow) and increased COX-2 immunostaining (panel e, arrow). In the Keto/Caff group exposed to IH, daily inspection of the eyes from the time of administration of Keto to the time of euthanasia showed no adverse effects. This was confirmed by histopathological examination during IHR which showed no Pediatric RESEARCH 557
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Articles Aranda et al. Figure S3 online. Retinas from RA controls (panel A) show some HIF staining in the GCL, INL, and P layers; VEGF staining in the IPL, OPL, and P layers; VEGFR-2 staining in the IPL, OPL, ONL, and P layers; and COX-2 staining in the NFL, IPL, OPL, and P layers. In the placebo-treated IHR groups there was increased HIF 1α , VEGF, and COX-2 immunostaining (panel B). HIF 1α was predominantly stained in the cells invading the vitreous fluid, the retinal pigmented epithelium (RPE), and choroid (arrows). VEGF was increased in the NFL, GCL, IPL, OPL, ONL, and P, and COX-2 in the NFL, GCL, OPL, and P. Treatment with Keto/Caff moderately reduced VEGF and COX-2, but not HIF 1α in the P (panel c). Images are 40× magnification.
Effect on Retinal VEGF Signaling
Genes involved in VEGF signaling were selected from a panel of 84 genes and presented in Tables 4 (P14, IH) and Table 5 (P21,  IHR) . Data are fold expression compared to RA placebo controls (Sal/Sal) and were examined in retinas from three different animals in each group. Genes that were greater than fivefold up-or downregulated are presented in red font. At P14, significant changes in gene expression were noted only in the Sal/Sal IH and Keto/Caff IH groups. During the IHR phase, treatment with Keto and/or Caff resulted in major changes in retinal gene expression, particularly genes involved in proliferation, differentiation, and inflammation. Caff appeared to have significant effects on VEGFR-3.
DISCUSSION
This study demonstrated that Keto or Caff given alone reduced retinal neovascularization, but given together may prevent severe OIR in this neonatal rat model. Co-administration of Keto with Caff also enhanced maturation of the retinal neural circuitry more effectively than when administered individually. Moreover, Keto and Caff exerted synergistic or additive effects on retinal and serum growth factors including IGF-I and VEGF. These neonatal rat data may be useful in the development of pharmacotherapies targeted at prevention of ROP in the preterm newborn. Although the overall incidence of ROP has decreased, it still remains high with threshold ROP occurring in 5% of ELGANs in the United States, with as much as 30% of them becoming blind (24) . Our neonatal rat OIR model closely simulates frequent IH episodes experienced by ELGANs. Using this model, we have previously shown that IH was associated with a more severe form of OIR (25-29) similar to ELGANs (4,5). We report here that ocular Keto and systemic Caff together exert a synergistic protective effect on OIR. Previous studies showed Articles that Caff decreases severe ROP (13, 14) and NSAIDs may prevent ROP in humans (21-23) and animal models (18, 20, 30) . Caffeine has been used in combination with NSAIDs for many decades to enhance their analgesic and anti-inflammatory effects (31) (32) (33) , suggesting that caffeine may be an effective adjuvant to NSAIDs. Thus, Caff may potentiate the effects of NSAIDs by preventing the cascade of events leading to severe OIR. Further evidence of the beneficial effects of Keto/Caff coadministration is presented in Table 3 . Eye opening in rodents is a key indicator of retinal maturation and development of the retinal neural circuitry (34, 35) . Keto/Caff cotreatment in IH accelerated visual maturation and significantly shortened the caecal period compared to the placebo-treated rats exposed to IH. Vascular growth factors are critical in angiogenesis and VEGF is in the promoting angiogenesis via activation of its receptors expressed on vascular endothelial cells. VEGF relies on IGF-I as a permissive factor which may be impaired in babies with severe ROP (36) . The present study shows that the level of growth factors in the systemic circulation does not necessarily represent that in the ocular compartment. Ocular Keto had no effect on systemic VEGF or IGF, but had a moderate suppressive effect on systemic sVEGFR-1 at P14. Conversely, ocular Keto had significant effects on growth factors in the retina and choroid. Acuvail (ketorolac tromethamine ophthalmic solution 0.45%) is a nonpreserved, isotonic ophthalmic solution with analgesic, ant-inflammatory, and antipyretic activity and contains carboxymethylcellulose (CMC), sodium chloride, and sodium citrate with a pH of 6.8. The benefit of CMC is its ability to enhance ocular bioavailability and tolerability. This may account for the increased absorption and ocular penetration of the drug. The responses of growth factors to the drugs are not uniform in RA and IH, suggesting that IH itself may interfere with drug activity. The effect of IH on retinal and choroidal HIF 1α levels has not been previously studied. Data showed that continuous IH episodes increased HIF 1α in the retina, but not in the choroid, during IH and IHR. This response was reversed with Keto/Caff treatment during IH, but not during IHR. However, Keto and Caff administered alone had significant suppressive effects on retinal HIF 1α which correlated with the changes in retinal VEGF. The effect of Caff on HIF 1α corroborates previous findings (37) and provides further evidence for a protective role of caffeine for prevention of VEGF overproduction and subsequent neovascularization.
Soluble VEGFR-1 (sVEGFR-1) is an endogenous negative regulator of VEGF. It acts as a VEGF "trap" by binding VEGF and preventing its availability to the membrane VEGF receptors. It was of great interest that in the placebo-treated groups at P14 and more so at P21, sVEGFR-1 levels were low to nondetectable in the retina. This finding was consistent with severe OIR production as demonstrated in 4E and 4M and suggests that OIR resulting from IH may include in part, reductions in sVEGFR-1. Treatment with Keto, Caff, and their combination, increased retinal and choroidal sVEGFR-1, suggesting a better modulation of retinal angiogenesis and prevention or minimization of aberrant neovascularization. The increase in sVEGFR-1 was even more marked during IHR, which has consistently been shown in our model, to be associated with severe OIR. It is possible that the beneficial effects of combined Keto/Caff may be due to induction of sVEGFR-1 acting as a VEGF "trap". As an alternate therapeutic approach, it would be interesting to see if strategic pharmacologic interventions at the time of onset of reoxygenation would result in a better outcome as opposed to early postnatal treatment. Ongoing studies in our laboratory will address this issue. IGF-1 serves as a permissive factor for VEGF action (36) . IGF-1 may therefore be another target for the protective effect of these drugs in the OIR. Retinal IGF-1 was significantly decreased by IH which is consistent with the notion that babies with severe OIR and oxidative injury have lower IGF-1 (36). This finding was not reflected in the serum. Instead, IH induced serum IGF-I levels and Keto cotreatment with Caff reversed the suppressive effect of IH on retinal and choroidal IGF-I. Consistent with human ROP, our OIR model presents with more severe OIR during the IHR phase. In this report, we show a relative lack of gene response to IHR in the retinas of placebo-treated animals exposed to IH. In contrast, Keto and/ or Caff had profound effects, resulting in several fold change in many of the protective genes compared to room air placebo controls. These include upregulation of heat-shock protein (Hsp) which protects tissues from various insults and participate in the repair of damaged tissue; mitogen-activated protein kinase (MAPK)-11, also known as p38-β is one of the four p38 MAPKs which play an important role in the cascades of cellular responses to stress; and phosphoinositide 3 kinase which is involved in preservation of photoreceptor structure and function (38) ; VEGFR-3; and NP-1. Studies suggest that VEGFR-3 may be upregulated in the absence of VEGF signaling (39) . Therefore, upregulation of VEGFR-3 with Keto and/or Caff may be one mechanism of protection against angiogenesis. NRP-1 is a coreceptor for both VEGF and semaphorins which are involved in normal angiogenesis, axon guidance, axon repulsion and migration. It increases the potency of, and is specific for, the VEGF 165 isoform. However, there is no response to VEGF 165 in the absence of VEGFR-2 expression. Downregulated genes include nuclear factor of activated T cells (Nfat)-5, which is highly upregulated by hypoxia, PKCα which is involved in proliferation of retinal pigmented epithelial cells, and VEGF-B which is critical for VEGFR-1 binding and plasminogen activation during tissue remodeling (40) .
Caff significantly decreased the risk of severe OIR, but did not prevent it completely, as was shown in the Caffeine for Apnea of Prematurity trial (12, 13) , unless given with ketorolac. We conclude that local ophthalmic ketorolac is probably safe and has no adverse local effect on the cornea, lens nor on the conjunctiva. Keto co-administration with Caff exerts a strong synergistic or additive effect to prevent OIR in this Genes of interest are as described in Table 4 . Data are compared to Sal/Sal in Room Air (RA); IH (intermittent hypoxia); IP (intraperitoneal). Minus value = downregulated. Ocular saline+IP saline (Sal/Sal); Ocular ketorolac+IP saline (Keto/Sal); Ocular saline+IP caffeine (Sal/Caff ); Ocular ketorolac+IP caffeine (Keto/Caff ).
